NIH awards grant to develop a new drug to treat narcolepsy Reset
Therapeutics, the leader in harnessing the power of the body’s
internal clocks to develop therapeutics, has been awarded a
five-year cooperative agreement by the National Institutes of
Health (NIH) to develop a new drug to treat narcolepsy. The
award was made through the NIH Blueprint Neurotherapeutics
Network, which was established in order to bridge the gap in
neuroscience-related drug development between academic and
industry research. Narcolepsy affects nearly 500,000 people in
the United States, Europe, and Japan. The majority of narcolepsy
patients also experience cataplexy (brief but debilitating
episodes of sudden-onset muscle weakness). None of the drugs
marketed for narcolepsy address the underlying cause of the
disease and full restoration of alertness remains a challenge
for many narcolepsy patients. Additionally, agents approved for
treating the symptoms of narcolepsy typically have limited
duration of action and are associated with